Get the Stockscreener App
43.29
6.30%
-2.8778
Cytokinetics Inc stock is traded at $43.29, with a volume of 1.92M.
It is down -6.30% in the last 24 hours and down -10.82% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$46.17
Open:
$46.23
24h Volume:
1.92M
Relative Volume:
1.57
Market Cap:
$5.45B
Revenue:
$3.22M
Net Income/Loss:
$-576.40M
P/E Ratio:
-8.0469
EPS:
-5.38
Net Cash Flow:
$-407.05M
1W Performance:
-12.53%
1M Performance:
-10.82%
6M Performance:
-15.53%
1Y Performance:
-43.90%
1-Day Range:
$43.04
$46.23
1-Week Range:
$43.04
$51.63
52-Week Range:
$43.04
$81.36
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
43.31 | 5.45B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics stock draws new Buy from Citi (CYTK:NASDAQ) - Seeking Alpha
Citi sets $86 price target on Cytokinetics stock with buy rating - Investing.com UK
FY2024 Earnings Forecast for Cytokinetics Issued By B. Riley - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target By Investing.com - Investing.com UK
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Positive Outlook for Cytokinetics Amid Rising HCM Market Demand and Developments - TipRanks
Cytokinetics’ Aficamten Poised for Market Success Amid Competitive Dynamics and Expanding HCM Opportunities - TipRanks
Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics Leadership Reveals Strategic Vision at Major Healthcare Conference - StockTitan
B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating -February 05, 2025 at 09:33 am EST - Marketscreener.com
Cytokinetics Lures Top Talent With Multi-Million Dollar Equity PackageStrategic Growth Plan Revealed - StockTitan
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - MSN
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm - The Malaysian Reserve
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm -January 30, 2025 at 12:23 pm EST - Marketscreener.com
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Cytokinetics awards $100K to heart disease advocacy groups - Investing.com
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program - GlobeNewswire
5 Patient Groups Share $100K Prize as Cytokinetics Backs Critical Heart Disease Programs - StockTitan
Nisa Investment Advisors LLC Sells 370 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
What Are Analysts Talking About Cytokinetics (CYTK)? - Insider Monkey
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Cantor Fitzgerald Predicts Cytokinetics FY2025 Earnings - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $91,840.00 in Stock - MarketBeat
Cytokinetics started at buy by Stifel, aficamten highlighted - MSN
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Stifel Nicolaus - MarketBeat
Cantor Fitzgerald Weighs in on Cytokinetics FY2025 Earnings - MarketBeat
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com - Investing.com Canada
Stifel starts Cytokinetics stock with Buy, $80 target - MSN
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from HC Wainwright - MarketBeat
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 - GlobeNewswire
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - Yahoo Finance
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook - Investing.com
Cytokinetics (NASDAQ:CYTK) Given "Market Outperform" Rating at JMP Securities - MarketBeat
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag - Barron's
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire
Cytokinetics Sets FDA Review Date for Aficamten, Unveils Ambitious 2030 Global Expansion Plan - StockTitan
HC Wainwright Reiterates “Buy” Rating for Cytokinetics (NASDAQ:CYTK) - Defense World
Cytokinetics EVP sells shares worth $98,640 By Investing.com - Investing.com South Africa
Cytokinetics EVP sells shares worth $98,640 - Investing.com India
Cytokinetics (NASDAQ:CYTK) Sets New 1-Year LowTime to Sell? - MarketBeat
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Feb 04 '25 |
Sale |
48.06 |
2,000 |
96,120 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Sale |
45.92 |
2,000 |
91,840 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Sale |
49.32 |
2,000 |
98,640 |
116,071 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):